Business Description
Neovacs SA
NAICS : 325412
SIC : 2834
ISIN : FR001400MV37
Compare
Compare
Traded in other countries / regions
ALNEV.France0LW0.Germany0W8U.UK IPO Date
2013-12-18Description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.36 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.21 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.09 | |||||
Beneish M-Score | -2469.22 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 96.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 72.59 | |||||
9-Day RSI | 46.02 | |||||
14-Day RSI | 40 | |||||
6-1 Month Momentum % | -99.77 | |||||
12-1 Month Momentum % | -100 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.25 | |||||
Quick Ratio | 1.25 | |||||
Cash Ratio | 0.29 | |||||
Days Sales Outstanding | 161.08 | |||||
Days Payable | 1621.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -12975 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 5.62 | |||||
Operating Margin % | -2306.18 | |||||
Net Margin % | -1637.27 | |||||
FCF Margin % | -396.44 | |||||
ROE % | -17.69 | |||||
ROA % | -15.91 | |||||
ROIC % | -23.21 | |||||
ROC (Joel Greenblatt) % | -1928.06 | |||||
ROCE % | -18.82 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | 0.02 | |||||
EV-to-EBITDA | 0.06 | |||||
EV-to-Revenue | -0.36 | |||||
EV-to-FCF | 0.09 | |||||
Earnings Yield (Greenblatt) % | 5000 | |||||
FCF Yield % | -4602.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neovacs SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.534 | ||
EPS (TTM) (€) | -30825.983 | ||
Beta | 0 | ||
Volatility % | 965.21 | ||
14-Day RSI | 40 | ||
14-Day ATR (€) | 0.00246 | ||
20-Day SMA (€) | 0.001085 | ||
12-1 Month Momentum % | -100 | ||
52-Week Range (€) | 0.0001 - 400 | ||
Shares Outstanding (Mil) | 28.53 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Neovacs SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Neovacs SA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Neovacs SA Frequently Asked Questions
What is Neovacs SA(STU:0LW0)'s stock price today?
The current price of STU:0LW0 is €0.00. The 52 week high of STU:0LW0 is €400.00 and 52 week low is €0.00.
When is next earnings date of Neovacs SA(STU:0LW0)?
The next earnings date of Neovacs SA(STU:0LW0) is .
Does Neovacs SA(STU:0LW0) pay dividends? If so, how much?
Neovacs SA(STU:0LW0) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |